Lupin and DKSH have signed an exclusive license and supply agreement to commercialize five of Alvotechs proposed biosimilars in the Philippines. The biosimilars planned under this agreement include biosimilar Prolia, Xgeva, Simponi, and Eylea as well as two undisclosed proposed biosimilars for immunology and oncology.
According to the agreement, Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
These reference products are used to treat disorders relating to bone disease, oncology, immunology and ophthalmology. This agreement enhances Multicare’s oncology, rheumatology, gastroenterology and ophthalmology portfolio, which currently consists of three biosimilar candidates and over 50 generic medicines.
“We are pleased to announce the addition of five new biosimilar candidates to our portfolio, which will provide patients in Philippines with effective, high-quality and affordable treatment options,” said Gabriel Georgy, Regional Head Southeast Asia, Lupin.
Peter Dolinsky, Vice President Own Brands, Asia Pacific at DKSH added, “We are delighted to partner with Lupin and bring these important therapeutic offerings to patients in the Philippines. This partnership is in line with our purpose of enriching people’s lives, and we are proud to be working with a strong local partner to make this happen.”
